Antimalarial Activity and Mechanisms of Action of Two Novel 4-Aminoquinolines against Chloroquine-Resistant Parasites

Abstract

Chloroquine (CQ) is a cost effective antimalarial drug with a relatively good safety profile (or therapeutic index). However, CQ is no longer used alone to treat patients with Plasmodium falciparum due to the emergence and spread of CQ-resistant strains, also reported for P. vivax. Despite CQ resistance, novel drug candidates based on the structure of CQ continue to be considered, as in the present work. One CQ analog was synthesized as monoquinoline (MAQ) and compared with a previously synthesized bisquinoline (BAQ), both tested against P. falciparum in vitro and against P. berghei in mice, then evaluated in vitro for their cytotoxicity and ability to inhibit hemozoin formation. Their interactions with residues present in the NADH binding site of P falciparum lactate dehydrogenase were evaluated using docking analysis software. Both compounds were active in the nanomolar range evaluated through the HRPII and hypoxanthine tests. MAQ and BAQ derivatives were not toxic, and both compounds significantly inhibited hemozoin formation, in a dose-dependent manner. MAQ had a higher selectivity index than BAQ and both compounds were weak PfLDH inhibitors, a result previously reported also for CQ. Taken together, the two CQ analogues represent promising molecules which seem to act in a crucial point for the parasite, inhibiting hemozoin formation.

About the Authors:

Anna Caroline Campos Aguiar

Affiliations Centro de Pesquisas René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil, Programa de Pós Graduação em Medicina Molecular, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil

Raquel de Meneses Santos

Affiliation: Instituto de Química e Biotecnologia, Universidade Federal do Alagoas, Maceió, Alagoas, Brazil

Flávio Júnior Barbosa Figueiredo

Affiliation: Centro de Pesquisas René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil

Wilian Augusto Cortopassi

Affiliations Laboratório de Modelagem Molecular Aplicada a Defesa Química e Biológica (LMDQB), Instituto Militar de Engenharia, Rio de Janeiro, Rio de Janeiro, Brazil, Departamento de Química, Pontifícia Universidade Católica do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil

André Silva Pimentel

Affiliation: Departamento de Química, Pontifícia Universidade Católica do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil

Tanos Celmar Costa França

* E-mail: [email protected] (AUK); [email protected] (MRM); [email protected] (TCCF)

Affiliation: Laboratório de Modelagem Molecular Aplicada a Defesa Química e Biológica (LMDQB), Instituto Militar de Engenharia, Rio de Janeiro, Rio de Janeiro, Brazil

Mario Roberto Meneghetti

* E-mail: [email protected] (AUK); [email protected] (MRM); [email protected] (TCCF)

Affiliation: Instituto de Química e Biotecnologia, Universidade Federal do Alagoas, Maceió, Alagoas, Brazil

Antoniana Ursine Krettli

* E-mail: [email protected] (AUK); [email protected] (MRM); [email protected] (TCCF)

Affiliations Centro de Pesquisas René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil, Programa de Pós Graduação em Medicina Molecular, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil

Introduction

Malaria is one of the most prevalent parasitic diseases in the world. It affects approximately 500 million individuals throughout the tropical and subtropical areas of developing countries and causes considerable morbidity and mortality with about 800,000 deaths worldwide each year [1]. P. falciparum infection in non-immune adults and children is often associated with severe cerebral malaria. The global importance of this disease, current limitations of vector control and the absence of an effective vaccine, makes the development of therapeutic antimalarial drugs the main strategy of malaria control [2].

CQ is a cost effective antimalarial drug with a relatively good safety profile [3]. However, CQ is no longer used alone due to the emergence and spread of P. falciparum CQ-resistant strains and, more recently, of P. vivax [4]–[6]. Artemisinin-based combination therapy (ACT) is the first line treatment in P. falciparum malaria (WHO, 2009). However, the limited availability of ACT and the decreased susceptibility of P. falciparum to artemisinin derivatives [7]–[8] have required the development of novel antimalarial drugs [9]–[11]. Previous studies have described the discovery of novel antimalarial drugs through analysis of medicinal plants [12] and through novel drug synthesis protocols [13]–[14], however, no new active compound has been shown to be as effective as CQ.

Despite the resistance of P. falciparum to CQ, novel drug candidates based on the structure of CQ continue to be considered [15]–[18]. In the present work, CQ analogs were synthesized as mono- and bisquinoline-based derivatives, referred as MAQ and BAQ, respectively. The main structural aspects considered included the maintenance of the 4-aminoquinoline pharmacophore group and the presence of proton-accepting sites to increase drug bioavailability in the digestive vacuole of the parasite. The compounds were tested: (i) as blood schizonticides against P. falciparum in vitro and against P. berghei malaria in mice; (ii) for their in vitro cytotoxicity; (iii) for their ability to inhibit hemozoin formation; and (iv) for their binding mode to lactate dehydrogenase and dimeric hematin in silico.

Results

Synthesis and characterization of CQ analogs

The structure of the two aminoquinoline derivatives, MAQ and BAQ, and their synthesis strategy are depicted in Scheme S1. Both CQ analogs possess the conserved 4-aminoquinoline moiety (a crucial pharmacophore group), and have a chlorine substituent at the 7 position on the quinoline ring, and, both have amino groups on the alkyl chain [19]. MAQ, a new monoquinoline molecule, and BAQ, a previously synthesized bisquinoline already tested against P. falciparum and proven to be active [20], were prepared from 4,7-dichloroquinoline and diethylenetriamine. These reactions occurred via a SNAr synthesis step, which eliminated the use of solvents [21]. MAQ and BAQ were obtained by controlling the stoichiometric relationship between these reagents. The synthesis protocol for the bisquinoline compound BAQ was described previously [20].

[Figure omitted. See PDF.]

Table 1. The anti-P. falciparum activities of BAQ and MAQ determined in parallel with chloroquine, by the ELISA anti-HRPII assay or by 3H hypoxanthine incorporation.

https://doi.org/10.1371/journal.pone.0037259.t001

BAQ and MAQ were isolated as white solids, which underwent a satisfactory elemental analysis and were fully characterized by NMR and IR spectroscopy. On the 1H NMR spectrum, MAQ showed five of the expected signals of the aromatic region (between 8.32 and 6.50 ppm) and four signals related to the methylenic groups (between 3.47 and 2.78 ppm). The hydrogen signals of the amino groups were either not present or had an integration level lower than the predicted value due to the fast H/D exchange with the deuterated solvent. In the 13C NMR spectrum, it was possible to identify nine signals related to the aromatic carbons (between 152 and 97 ppm) and the four signals associated with the methylenic carbons (50 to 40 ppm). In the infrared spectrum of MAQ, the typical absorption bands for this kind of chemical structure were observed and the 1H NMR spectrum was consistent with the five typical aromatic signals (between 8.25 and 6.46 ppm). However, only two signals related to the methylenic groups were observed due to the symmetry of the molecule (3.45 and 2.95 ppm). In the 13C NMR spectrum of BAQ, the expected nine signals related to the aromatic carbons (between 152 and 97 ppm) and the two possible signals of the methylenic carbons (46.8 and 41.8 ppm) were observed. The infrared spectrum of BAQ exhibited the absorption bands predicted for this structure.

BAQ and MAQ activities against P. falciparum in vitro

The 4-aminoquinoline derivatives MAQ and BAQ were compared with CQ for their antiplasmodial activities against the W2 clone of P. falciparum (CQ-resistant and mefloquine-sensitive) and against a CQ-sensitive strain 3D7. All compounds showed activity in the nanomolar range in the HRPII and hypoxanthine tests (Table 1). The IC50 values were similar in both assays, although somewhat lower for BAQ in the hypoxanthine test with W2 parasites. As expected, the IC50 values of BAQ and MAQ were lower with the CQ- sensitive 3D7 strain than with W2 CQ- resistant in most tests.

Neither MAQ or BAQ were toxic against hepatoma (HepG2) or kidney (BGM) cell lines, and important, the new CQ analog MAQ was less toxic than BAQ, based on MTT assay (Table 2) or neutral red method (data not shown). Additionally, the CQ analogs were not lytic to human erythrocytes. Even at doses 100 times higher than the IC50 values no hemolysis was detected.

[Figure omitted. See PDF.]

Table 2. Cytotoxicity of BAQ and MAQ against a human hepatoma cell line (HEPG2) and a monkey kidney cell line (BGM) determined by the MTT assay.

https://doi.org/10.1371/journal.pone.0037259.t002

The selectivity index- IS (the ratio between MDL50 and IC50) was determined and both compounds had an IS greater than 90. The IS was particularly high for MAQ, 384 and 1038, against BGM and HepG2 cells respectively (Table 2). Nevertheless, neither compound was better then CQ (IS>3083)

BAQ and MAQ were also active in vivo against rodent malaria

The antimalarial activity of the new CQ analogs was evaluated in mice with P. berghei and is summarized in Table 3. MAQ and BAQ were active in vivo at a dose of 50 mg/kg on days 5, 8 and 10 days post-infection, at 25 mg/kg only MAQ was active. MAQ caused a 95% reduction of parasitemia on day 5. However, only CQ caused 100% suppression of parasitemia and increased the animal survival, but the survival differences were not significant from the other groups.

[Figure omitted. See PDF.]

Table 3. Antimalarial activity of BAQ and MAQ in mice infected with P. berghei after treatment with daily doses of the compounds during three consecutive days.

https://doi.org/10.1371/journal.pone.0037259.t003

The antimalarial activity of BAQ and MAQ involves inhibition of hemozoin formation

Whether anti P. falciparum activity of BAQ and MAQ involves inhibition of hemozoin formation was evaluated using an indirect in vitro test. Both compounds significantly inhibited hemozoin formation in vitro (Figure 1) in a dose-dependent reaction. The inhibition was more evident with MAQ than with BAQ or CQ (Figure 1A).

[Figure omitted. See PDF.]

Figure 1. Inhibition of hemozoin formation by the CQ analogs BAQ and MAQ (mean ± SD from triplicates), in two different experiments.

Statistical differences as compared to drug-free controls are indicated in each graph by an asterisk (p<0.05). The p and r values represent the statistical correlation analyses.

https://doi.org/10.1371/journal.pone.0037259.g001

Similarly, docking studies with MAQ and BAQ showed that the MolDock Score energies between the antimalarials and the dimeric hematin (Table 4) were approximately –100.000 kcal mol–1. Both aminoquinoline derivatives, similar to CQ, were able to interact with dimeric hematin to form a complex. The best conformations (Figure 2) obtained for the complexes showed that the aromatic rings of both compounds were parallel to the hematin ferriprotoporphyrin group (Figure 3). Weak hydrogen bonds (approximately −5.0 kcal mol–1) corroborate previous studies demonstrating that the hydrophobic interactions were the main contributors for the binding between CQ and the dimer [22]–[23].

[Figure omitted. See PDF.]

Figure 2. Chemical structures of the protonated forms of the CQ analogs BAQ and MAQ.

https://doi.org/10.1371/journal.pone.0037259.g002

[Figure omitted. See PDF.]

Figure 3. Compounds docked in dimeric hematin.

(A) Protonated CQ, (B) MAQ-1, (C) MAQ-2, (D) MAQ-3, (E) BAQ-1, (F) BAQ-2.

https://doi.org/10.1371/journal.pone.0037259.g003

[Figure omitted. See PDF.]

Table 4. Docking energies of the protonated forms of the CQ analogs BAQ and MAQ.

https://doi.org/10.1371/journal.pone.0037259.t004

The antimalarial action of BAQ and MAQ involves binding to lactate dehydrogenase

Table 5 presents the H-bond energy and MolDock Scores of the residues involved in H-bonds with NADH as well as the protonated forms of chloroquine, BAQ and MAQ docked to PfLDH. Figure 4 shows that these compounds presented the most stable energy conformations in the binding site of NADH. This suggests that they are NADH competitors. The H-bond energy between the protonated chloroquine and the enzyme was −3.8 kcal mol−1, a high value compared with that of NADH H-bond energy (−35.3 kcal mol−1). The energy of interaction between the enzyme and the protonated forms of MAQ were approximately −250.00 kcal mol−1. Furthermore, MAQ like the protonated chloroquine, bound to the active site of PfLDH; BAQ-1 and BAQ-2 presented the lowest energies, which were extremely large when compared to NADH. These findings suggest that all these compounds are weak inhibitors of PfLDH, as previously reported for chloroquine [24].

[Figure omitted. See PDF.]

Figure 4. Best conformations of the protonated forms of chloroquine, MAQ and BAQ (in green) in the binding pocket of NADH (in CPK) as generated by the MVD® software.

(A) Protonated chloroquine, (B) MAQ-1, (C) MAQ-2, (D) MAQ-3, (E) BAQ-1, (F) BAQ-2.

https://doi.org/10.1371/journal.pone.0037259.g004

[Figure omitted. See PDF.]

Table 5. Docking results of NADH and the protonated forms of chloroquine, BAQ and MAQ in the active site of PfLDH.

https://doi.org/10.1371/journal.pone.0037259.t005

Discussion

A large series of bisquinoline derivatives containing proton-accepting amino groups on the aliphatic chain moiety has already been described [19] and considered a promising class of compounds for treating drug-resistant malaria parasites. Two CQ analogs MAQ and BAQ were obtained as low-cost antimalarial prototypes, which is important considering that disease transmission is concentrated in developing countries and is most frequent among the impoverished classes of several endemic countries [9]. Comparisons between their antimalarial activities aimed to evaluate the molecular structural-activity relationship between mono- and bisquinoline compounds.

We showed that MAQ and BAQ are active in vitro against CQ-resistant and CQ-sensitive P. falciparum parasites at nanomolar doses in the hypoxanthine incorporation test and in an enzyme-linked immunosorbent assay (ELISA), using antibodies against the histidine-rich protein 2 (HRP-II), a parasite protein.Our results show that MAQ, a new monoquinoline, has a higher IS, in consonance with the tendency of a decreased toxicity when comparing mono- to bisquinoline analogs. Such in vitro activity was confirmed in vivo in mice infected with P. berghei; MAQ was more effective as proven by parasitemia reduction in response to drug treatment.

Further in vitro analysis showed that the compounds interacted with dimeric hematin and inhibited heme polymerization. Although the mechanism of action of CQ is not well understood, several experimental studies describe the interaction between CQ and the dimeric form of heme [25], [26], [27], [28]. This interaction seems responsible for the inhibition of hemozoin formation, a hypothesis further supported by docking studies, which also suggest that all protonated forms of MAQ and BAQ interact with the rings parallel to the heme group, as described previously for CQ [26], [27], [28], [29].

The presence of two quinoline moieties in BAQ increases the probability of hydrophobic interactions when compared with MAQ and also results in lower docking energies for all protonation states of the amino groups. The results of this study suggest that the protonated BAQ at the central nitrogen (BAQ-1) should be more effective at inhibiting heme polymerization.

Experimental and modeling studies have shown that chloroquine binds to PfLDH, suggesting that CQ possesses another mechanism of drug action or a mechanism complementary to the one already proposed [24], [29]. Although PfLDH is not a direct chloroquine target, experimental data have shown its weak binding to chloroquine [30]. The existence of this shared target-binding site suggests that PfLDH is related to drug effectiveness. The docking data (Figure 4) suggest that the protonated forms of BAQ and MAQ present the most stable energetic conformations at the binding site of NADH inside PfLDH. The H-bond energy and MolDock Scores, the residues involved in the H-bonds with NADH and the protonated forms of chloroquine as well as BAQ and MAQ binding to PfLDH (Table 5) suggest that these compounds are NADH competitors. The H-bond energy between protonated chloroquine and the enzyme is −3.8 kcal mol−1, a high value compared with the H-bond energy of NADH (−35.3 kcal mol−1). The energies of interaction between the enzyme and the protonated forms of MAQ were approximately –250.0 kcal mol−1. Furthermore, MAQ compounds showed a similar behavior at the active site of PfLDH compared with protonated chloroquine. BAQ-1 and BAQ-2 possessed the lowest energies, which were extremely large compared with NADH. Overall, these findings suggest that all of these compounds are weak inhibitors of PfLDH, as previously reported for chloroquine [22]–[23].

One of the recent strategies to develop effective antimalarial agents is based on the development of metal-drugs [31], [32], [33]. Thus, MAQ and BAQ were associated with metals readily available to be tested for their antimalarial activity, in promising ongoing tests (data not shown). Metallocomplexed drugs, considered first-line anticancer drugs [34], [35], are increasingly used to develop anti-parasitic agents [36], [37], [38].

Materials and Methods

Reagents and drug synthesis

All reactions for drug synthesis were performed under a 100% argon atmosphere using a dual vacuum/argon line and standard Schlenk techniques. Reagents and solvents were purchased from Sigma Aldrich and used without further purification. The IR spectra were recorded on a Varian 640-IR with an ATR device and the elementary analyses were conducted at the analytical center, University of São Paulo. The 1H NMR spectra were recorded at 400.130 MHz and the 13C NMR spectra at 100.613 MHz on a Bruker instrument (Bruker Avance 400) and were externally referenced to the tetramethylsilane (TMS). Chemical shifts (δ) and coupling constants (J) were expressed in ppm and Hz, respectively. The melting or decomposition points of the structures were determined on a MQAPF 302 apparatus.

Synthesis of the 4-aminoquinolines, MAQ and BAQ

MAQ, N1-(2-aminoethyl)-N2-(7-chloroquinol-4-yl)ethane-1,2-diamine, was prepared according to the synthesis procedures described by Musonda and collaborators [39]. Briefly, a mixture of 4,7-dichloroquinoline (0.98 g, 4.9 mmol) and diethylenetriamine (2.7 mL, 25 mmol) was heated at 80°C for 1 h without stirring, following by heating at 135°C for 3 h with stirring. The mixture was cooled to room temperature, alkalized with an aqueous solution of 10% NaOH (30 mL), extracted with hot EtOAc (3×50 mL) and dried over Na2SO4. The solvent was removed under vacuum and the residue was crystallized with CH2Cl2/hexane, thereby leading to a white solid. Chemical and spectral analyses revealed the following: Yield: 0.52 g, 40%. M.F: C13H17ClN4; M.M.: 264.75 g/mol. Elem. Anal., theoretical: C13H17ClN4, C, 58.98; H, 6.47; N, 21.16, experimental: C13H17ClN4.H2O, C, 55.23; H, 6.54; N, 19.22. M.P.: 99–100°C; I.R. (νmáx cm−1): 3256 (Ar- NH); 3065 (CH quinoline ring); 2929 and 2839 (CHas/s and CH2); 1607, 1577 and 1528 (C = C quinoline ring); 1449 (CH2); 1280 (Ar-C-N); 1133 (C-N); 874, 795 and 761 (δ = C-H out-of-plane aromatic ring). RMN 1H (400 MHz, CD3OD): δ 1.93 (s, NH amine), 2.78 (t, J = 5.76 Hz, 2H, CH2-16), 2.85 (t, J = 5.76 Hz, 2H, CH2-15), 2.95 (t, J = 6.38 Hz, 2H, CH2-13), 3.47 (t, J = 6.38 Hz, 2H, CH2-12), 3.70 (ls, NH aniline), 6.50 (d, J = 5.71 Hz, 1H, Ar-H C-3), 7.35 (dd, J = 9.01 Hz, J = 2.14 Hz, 1H, Ar-H C-6), 7.73 (d, J = 2.14 Hz, 1H, Ar-H C-8), 8.07 (d, J = 9.01 Hz, 1H, Ar-H C-5), 8.32 (d, J = 5.62 Hz, 1H, Ar-H C-2). RMN 13C (100 MHz, CD3OD): δ 151.1 (C-2), 98.28 (C-3), 151.4 (C-4), 124.6 (C-5), 123.08 (C-6), 134.9 (C-7), 126.2 (C-8), 148.2 (C-9), 117.32 (C-10), 50.03 (C-12), 42.08 (C-13), 39.9 (C-15), 38.46 (C-16).

BAQ, N1-(7-chloroquinol-4-yl)-N2-{2-[(7-chloroquinol-4-il)amino]ethyl}ethane-1,2-diamine, was synthesized according to the synthesis procedures described by Zhang and collaborators [40]. Briefly, a mixture of 4,7-dichloroquinoline (1.20 g, 6.00 mmol) and diethylenetriamine (0.22 mL, 2.00 mmol) was heated at 80°C for 6 h without stirring and then at 130°C for 3 h with stirring. The reaction mixture was cooled to room temperature and the resulting solid that formed was washed with an aqueous solution of 10% NaOH (30 mL) and recrystallized with MeOH/water. The solid was recuperated by filtration and dried under vacuum, which lead to a white solid. Chemical and spectral analyses revealed the following: Yield: 0.43 g, 50%. M.F: C22H21Cl2N5; M.M.: 426.34 g/mol. Elem. Anal., theoretical: C22H21Cl2N5, C, 61.98; H, 4.96; N, 16.43; experimental: C22H21Cl2N5.4H2O, C, 53.03; H, 4.91; N, 14.07. M.P.: 212–215°C; IR. (νmax in cm−1): 3272 (Ar- NH); 3071 (CH quinoline ring); 2901 and 2843 (CH2 as/s); 1608, 1576 and 1531 (C = C quinoline ring); 1441 (CH2); 1328 (Ar-CN); 1136 (C-N); 865 and 798 (δ out-of-plane aromatic ring). 1H RMN (400 MHz, CD3OD): δ 2.97 (t, J = 6.22 Hz, 2H, CH2-13), 3.45 (t, J = 6.24 Hz, 2H, CH2-12), 6.45 (d, J = 5.69 Hz, 1H, Ar-H C-3), 7.20 (dd, J = 9.01 Hz, J = 2.14 Hz, 1H, Ar-H C-6), 7.67 (d, J = 2.12 Hz, 1H, Ar-H C-8), 7.87 (d, J = 8.97 Hz, Ar-H C-5), 8.24 (d, J = 5.61 Hz, 1H, Ar-H C-2). RMN 13C (100 MHz, MeOD): δ 150.9 (C-2), 98.3 (C-3), 151.2 (C-4), 124.6 (C-5), 122.6 (C-6), 134.9 (C-7), 126.2 (C-8), 148.14 (C-9), 117.3 (C-10), 46.8 (C-12), 41.8 (C-13).

Continuous cultures of P. falciparum

P. falciparum blood parasites (W2 clone, CQ-resistant and mefloquine-sensitive) were maintained in continuous culture as previously described [41] with slight modifications [42]. The 3D7 strain, CQ- sensitive, originally received from the New York University Medical School, was also used. Briefly, the parasites were kept at 37°C in human erythrocytes (A+) with complete medium (RPMI 1640 supplemented with 10% human serum blood group A+, 2% glutamine and 7.5% NaHCO3) in Petri dishes in a candle jar or in a 25-cm culture flask in a defined atmosphere (with 3% O2, 5% CO2 and 91% N2). Human erythrocytes (A+) and serum blood group A+ were kindly donated by Center of Hemotherapy and Hemathology of Minas Gerais (HEMOMINAS). Immediately before the tests, ring stage-parasites were synchronized in sorbitol [43]. Synchronized parasites were stained with orange green in pre-dried coverslips [44] then immediately examined under a fluorescent microscope. The suspension was adjusted for parasitemia and hematocrit as described below for each test. The infected red blood cells were distributed in a 96-well microtiter plate (Corning, Santa Clara, CA, EUA) at 180 µL/well, in which 20 µL of the test drugs and controls were previously diluted at different concentrations (400-0.625 ng/mL) in 0.005% DMSO (v/v) (Sigma, USA).

In vitro assays with P. falciparum infected erythrocytes

The effects of BAQ and MAQ on the W2 and 3D7 P. falciparum blood cultures were assayed through the incorporation of 3H hypoxanthine (PerkinElmer, Waltham, MA, EUA) [45] and with monoclonal antibodies to the parasite histidine and alanine-rich protein (HRPII) (MPFM ICLLAB-55A®, MPFG55P ICLLAB®, USA) (Noedl 2002). The [3H]-hypoxanthine assay was performed at 1% parasitemia and 1% hematocrit and the level of isotope incorporation was read in a beta-counter (PerkinElmer, Waltham, MA, EUA). The anti-HRPII test was performed at 0.05% parasitemia and 1.5% hematocrit and the HRPII quantification was read at 450 nm in a spectrophotometer (SpectraMax340PC384, Molecular Devices). The results of three of these drug activity assays were expressed as the mean of the half-maximal inhibitory dose (IC50) and compared with the drug-free controls. Curve-fitting was performed using Origin 8.0 software (OriginLab Corporation, Northampton, MA, USA) [46].

Inhibition of hemozoin assay

The hemozoin inhibition assay was performed as described by Ncokazi et al., (2002) [47] with some modifications. Briefly, 10.1 µL of the aminoquinoline derivatives at different concentrations (40-0.62 mg/mL) and 101.2 µL of the hematin stock solution (1.68 mM in 0.1 M NaOH) were combined in triplicate in a flat-bottomed 96-well plate. The solutions were further mixed and 58.7 µL of acetate solution (12.9 M, pH 5.0) then added to each well. After incubation at 60°C, 80 µL of 30% (v/v) pyridine solution in 20 mM HEPES, pH 7.5, were added at room temperature. The solids formed were resuspended and allowed to settle for 15 min at room temperature. Then, 38 µL of the supernatant were transferred to a new plate and diluted to 250 µL with a 30% (v/v) pyridine solution (20 mM HEPES, pH 7.5). The color reaction was read in a spectophometer at 405 nm and the results were expressed as the concentration of free heme in each well, which was calculated from the standard absorbance curve of a known hemin solution. CQ was used as a positive control and the cut off was determined by the amount of free heme in the drug-free control. Each compound was evaluated in two different experiments.

Antimalarial tests against P. berghei in mice

A suppressive parasite growth test was used with P. berghei, NK65 strain (originally received from the New York University Medical School) infected mice as described previously [48] with some modifications [49]. Briefly, adult Swiss outbred mice (20±2 g weigh) were inoculated with 1×105 red blood cells infected with P. berghei, by intraperitoneal route. The infected mice were maintained together for at least 2 h and then divided randomly into groups of 3–5 animals per cage, which were subsequently treated with 25 and 50 mg/kg of each compound diluted in DMSO 3% (v/v) given daily by oral gavage for three consecutive days. Two control groups were used in parallel, one treated with CQ (20 mg/kg) and one with the vehicle. Blood smears from mouse tails were prepared on days 5, 8 and 10 post-infection and then methanol-fixed, stained with Giemsa and examined microscopically. The parasitemia was evaluated and the percent inhibition of parasite growth calculated in relation to the untreated control group (considered 100% growth) using the following equation: [(C - T)/C] ×100; where C is the parasitemia in the control group and T is the parasitemia in the treated group.

The use of laboratory animals was approved by the Ethics Committee for Animal Use of the Oswaldo Cruz Foundation - Fiocruz (CEUA L-0046/08).

Cell cultures and cytotoxicity tests

The human hepatoma cell line (HepG2) was originally received from the New University of Lisbon, and the monkey kidney cell line (BGM) from the Federal University of Minas Gerais. These cells were cultured in 75 cm2 plates with RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum and 40 mg/L gentamicine in a 5% CO2 atmosphere at 37°C. For the in vitro tests, a confluent cell monolayer was trypsinized, washed with culture medium, distributed in a flat-bottomed 96-well plate (5×103 cells/well) and incubated for 18 h at 37°C to ensure cell adherence.

The cytotoxicity was evaluated with the MTT assay, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide [50]. Briefly, the HepG2 and BGM cell lines were incubated with 20 µL of the compounds at different concentrations (1000-1 µg/mL) for 24 h in a 5% CO2 and air atmosphere at 37°C. For the MTT assay, which evaluates mitochondrial viability, 20 µL of MTT solution (5 mg/mL) were added and the plates were incubated for a further 3 h. After incubation, the supernatant was carefully removed from the wells, followed by the addition of 100 µL DMSO with thorough mixing. The optical density at 570 and 630 nm (background) was determined on an ELISA reader (SpectraMax340PC384, Molecular Devices).

The neutral red assay was used to evaluate cell viability by the accumulation of dye in the viable cell lysosome [51]. Briefly, the cells were incubated for 2 h with 100 µL of a neutral red solution (100 µg/mL). Then, the supernatants were discard and 200 µL of a formaldehyde (0.5% v/v) and CaCl2 (1%) solution were added, which was followed by another 5 min incubation. Finally, the supernatant was removed, then 100 µL of an alcohol-acid solution added to the sediment. The absorbance was read at 540 nm on an ELISA reader (SpectraMax340PC384, Molecular Devices). Cell viability was expressed as the percentage of control absorbance obtained in untreated cells after subtracting the absorbance of the appropriate background. Lastly, the minimum lethal dose for 50% of the cells (MLD50) was determined as previously described [52].

Hemolysis assay

The test and control compounds were diluted in a 0.2% (v/v) DMSO solution and incubated (0–50 µg/mL) with a human erythrocytes suspension (1% hematocrit) at 37°C for 30 min in a shaking water bath. The mixtures were centrifuged at 1000 g for 10 min and the absorbance of the supernatants was measured at 540 nm in an ELISA reader (SpectraMax340PC384, Molecular Devices). The hemolytic rate was calculated in relation to the hemolysis of erythrocytes in 0.05% saponin, which was considered to be 100% [53].

Docking energy calculations

The 3D optimized structure of dimeric hematin was taken from our previous studies [29]. The structures of CQ and its analogs were built using the Gaussian View software and optimized using Gaussian 03 [54]. The structural analysis of CQ analogs (BAQ and MAQ) was performed and all possible protonation forms in the biological medium were considered (Figure 2). The geometry optimizations and partial atomic charge distributions were performed using the B3LYP/3-21G level of theory. The calculations for the docking energies were performed with Molegro Virtual Docker (MVD) software [55] as described previously [25]. The algorithm used in the docking studies was the MolDock Score, which is an adaptation of the Differential Evolution (DE) algorithm [53]. The MolDock Score was used because it yields a higher docking accuracy than other state-of-the-art docking algorithms (MVD: 87%, Glide: 82%, Surflex: 75%, FlexX: 58%) [46].

The 3D structure of PfLDH complexed with NADH and the substrate oxamate used in the present work was obtained from the Protein Data Bank (PDB) file 1LDG [56], [57]. We performed flexible docking studies (considering the presence of water molecules in the crystal) with the protonated forms of BAQ and MAQ to compare these interactions with protonated chloroquine at the active site of PfLDH.

Supporting Information

[Figure omitted. See PDF.]

Scheme S1.

Synthesis of MAQ and BAQ.

https://doi.org/10.1371/journal.pone.0037259.s001

(TIF)

Acknowledgments

We are grateful to Dr. Marcus Fernandes de Oliveira and Juliana B. R. Corrêa Soares for helping with the hemozoin assay.

Author Contributions

Conceived and designed the experiments: MRM TCCF AUK. Performed the experiments: ACCA FJBF WAC RMS ASP. Analyzed the data: ACCA FJBF WAC RMS ASP MRM TCCF AUK. Contributed reagents/materials/analysis tools: MRM TCCF AUK. Wrote the paper: ACCA WAC ASP MRM TCCF AUK.

Citation: Aguiar ACC, Santos RdM, Figueiredo FJB, Cortopassi WA, Pimentel AS, França TCC, et al. (2012) Antimalarial Activity and Mechanisms of Action of Two Novel 4-Aminoquinolines against Chloroquine-Resistant Parasites. PLoS ONE7(5): e37259. https://doi.org/10.1371/journal.pone.0037259

References

1. WHO (2010) WHO2010World Malaria Report 2010. Available at: http://www.who.int/malaria/world_malaria_report_2010/worldmalariareport2010.pdf. Accessed: march/2011. World Malaria Report 2010. Available at: http://www.who.int/malaria/world_malaria_report_2010/worldmalariareport2010.pdf. Accessed: march/2011.

2. de Ridder S, van der Kooy F, Verpoorte R (2008) Artemisia annua as a self-reliant treatment for malaria in developing countries. J Ethnopharmacol 120: 302–314.S. de RidderF. van der KooyR. Verpoorte2008Artemisia annua as a self-reliant treatment for malaria in developing countries.J Ethnopharmacol120302314

3. Greenwood BM, Bojang K, Whitty CJ, Targett GA (2005) Malaria. Lancet 365: 1487–1498.BM GreenwoodK. BojangCJ WhittyGA Targett2005Malaria.Lancet36514871498

4. Baird JK (2004) Chloroquine resistance in Plasmodium vivax. Antimicrob Agents Chemother 48: 4075–4083.JK Baird2004Chloroquine resistance in Plasmodium vivax.Antimicrob Agents Chemother4840754083

5. de Santana Filho FS, Arcanjo AR, Chehuan YM, Costa MR, Martinez-Espinosa FE, et al. (2007) Chloroquine-resistant Plasmodium vivax, Brazilian Amazon. Emerg Infect Dis. 13: 1125–1126.FS de Santana FilhoAR ArcanjoYM ChehuanMR CostaFE Martinez-Espinosa2007Chloroquine-resistant Plasmodium vivax, Brazilian Amazon. Emerg Infect Dis.1311251126

6. Tjitra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, et al. (2008) Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med 5: e128.E. TjitraNM AnsteyP. SugiartoN. WarikarE. Kenangalem2008Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia.PLoS Med5e128

7. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, et al. (2009) Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361: 455–467.AM DondorpF. NostenP. YiD. DasAP Phyo2009Artemisinin resistance in Plasmodium falciparum malaria.N Engl J Med361455467

8. Lin JT, Juliano JJ, Wongsrichanalai C (2010) Drug-Resistant Malaria: The Era of ACT. Curr Infect Dis Rep 12: 165–173.JT LinJJ JulianoC. Wongsrichanalai2010Drug-Resistant Malaria: The Era of ACT.Curr Infect Dis Rep12165173

9. Rosenthal PJ (2003) Antimalarial drug discovery: old and new approaches. J Exp Biol 206: 3735–3744.PJ Rosenthal2003Antimalarial drug discovery: old and new approaches.J Exp Biol20637353744

10. Krettli AU, Adebayo JO, Krettli LG (2009) Testing of natural products and synthetic molecules aiming at new antimalarials. Curr Drug Targets 10: 261–270.AU KrettliJO AdebayoLG Krettli2009Testing of natural products and synthetic molecules aiming at new antimalarials.Curr Drug Targets10261270

11. Enserink M (2010) If artemisinin drugs fail, what's plan B? Science 328: 846.M. Enserink2010If artemisinin drugs fail, what's plan B?Science328846

12. Krettli , AU (2009) Antimalarial drug discovery: screening of Brazilian medicinal plants and purifi ed compounds. Expert Opin. Drug Discov 4: 95–108.KrettliAU2009Antimalarial drug discovery: screening of Brazilian medicinal plants and purifi ed compounds. Expert Opin.Drug Discov495108

13. Cunico W, Cechinel C, Bonacorso H, Martins M, Zanatta N, et al. (2006) Antimalarial activity of 4-(5-trifluoromethyl-1H-pyrazol-1-yl)-chloroquine analogues. Bioorg Med Chem Lett 16: 649–653.W. CunicoC. CechinelH. BonacorsoM. MartinsN. Zanatta2006Antimalarial activity of 4-(5-trifluoromethyl-1H-pyrazol-1-yl)-chloroquine analogues.Bioorg Med Chem Lett16649653

14. de Pilla Varotti F, Botelho A, Andrade A, de Paula R, Fagundes E, et al. (2008) Synthesis, antimalarial activity, and intracellular targets of MEFAS, a new hybrid compound derived from mefloquine and artesunate. Antimicrob Agents Chemother 52: 3868–3874.F. de Pilla VarottiA. BotelhoA. AndradeR. de PaulaE. Fagundes2008Synthesis, antimalarial activity, and intracellular targets of MEFAS, a new hybrid compound derived from mefloquine and artesunate.Antimicrob Agents Chemother5238683874

15. Ryckebusch A, Debreu-Fontaine MA, Mouray E, Grellier P, Sergheraert C, et al. (2005) Synthesis and antimalarial evaluation of new N1-(7-chloro-4-quinolyl)-1,4-bis(3-aminopropyl)piperazine derivatives. Bioorg Med Chem Lett 15: 297–302.A. RyckebuschMA Debreu-FontaineE. MourayP. GrellierC. Sergheraert2005Synthesis and antimalarial evaluation of new N1-(7-chloro-4-quinolyl)-1,4-bis(3-aminopropyl)piperazine derivatives.Bioorg Med Chem Lett15297302

16. Yearick K, Ekoue-Kovi K, Iwaniuk DP, Natarajan JK, Alumasa J, et al. (2008) Overcoming drug resistance to heme-targeted antimalarials by systematic side chain variation of 7-chloro-4-aminoquinolines. J Med Chem 51: 1995–1998.K. YearickK. Ekoue-KoviDP IwaniukJK NatarajanJ. Alumasa2008Overcoming drug resistance to heme-targeted antimalarials by systematic side chain variation of 7-chloro-4-aminoquinolines.J Med Chem5119951998

17. Ekoue-Kovi K, Yearick K, Iwaniuk DP, Natarajan JK, Alumasa J, et al. (2009) Synthesis and antimalarial activity of new 4-amino-7-chloroquinolyl amides, sulfonamides, ureas and thioureas. Bioorg Med Chem 17: 270–283.K. Ekoue-KoviK. YearickDP IwaniukJK NatarajanJ. Alumasa2009Synthesis and antimalarial activity of new 4-amino-7-chloroquinolyl amides, sulfonamides, ureas and thioureas.Bioorg Med Chem17270283

18. Andrews S, Burgess SJ, Skaalrud D, Kelly JX, Peyton DH (2010) Reversal agent and linker variants of reversed chloroquines: activities against Plasmodium falciparum. J Med Chem 53: 916–919.S. AndrewsSJ BurgessD. SkaalrudJX KellyDH Peyton2010Reversal agent and linker variants of reversed chloroquines: activities against Plasmodium falciparum.J Med Chem53916919

19. Blackie MA, Yardley V, Chibale K (2010) Synthesis and evaluation of phenylequine for antimalarial activity in vitro and in vivo. Bioorg Med Chem Lett 20: 1078–1080.MA BlackieV. YardleyK. Chibale2010Synthesis and evaluation of phenylequine for antimalarial activity in vitro and in vivo.Bioorg Med Chem Lett2010781080

20. Girault S, Grellier P, Berecibar A, Maes L, Lemière P, et al. (2001) Antiplasmodial activity and cytotoxicity of bis-, tris-, and tetraquinolines with linear or cyclic amino linkers. J Med Chem 44: 1658–1665.S. GiraultP. GrellierA. BerecibarL. MaesP. Lemière2001Antiplasmodial activity and cytotoxicity of bis-, tris-, and tetraquinolines with linear or cyclic amino linkers.J Med Chem4416581665

21. Carey FA, Sundberg RJ (1990) Advanced Organic Chemistry Part B: Reactions and Synthesis, 3rd Ed, Plenum, New York pg 597: FA CareyRJ Sundberg1990Advanced Organic Chemistry Part B: Reactions and Synthesis, 3rd Ed, Plenum, New York pg597

22. Dorn A, Vippagunta S, Matile H, Jaquet C, Vennerstrom J, et al. (1998) An assessment of drug-haematin binding as a mechanism for inhibition of haematin polymerisation by quinoline antimalarials. Biochem Pharmacol 55: 727–736.A. DornS. VippaguntaH. MatileC. JaquetJ. Vennerstrom1998An assessment of drug-haematin binding as a mechanism for inhibition of haematin polymerisation by quinoline antimalarials.Biochem Pharmacol55727736

23. Portela C, Afonso CM, Pinto MM, Ramos MJ (2003) Receptor-drug association studies in the inhibition of the hematin aggregation process of malaria. FEBS Lett 547: 217–222.C. PortelaCM AfonsoMM PintoMJ Ramos2003Receptor-drug association studies in the inhibition of the hematin aggregation process of malaria.FEBS Lett547217222

24. Menting J, Tilley L, Deady L, Ng K, Simpson R, et al. (1997) The antimalarial drug, chloroquine, interacts with lactate dehydrogenase from Plasmodium falciparum. Mol Biochem Parasitol 88: 215–224.J. MentingL. TilleyL. DeadyK. NgR. Simpson1997The antimalarial drug, chloroquine, interacts with lactate dehydrogenase from Plasmodium falciparum.Mol Biochem Parasitol88215224

25. Penna-Coutinho J, Cortopassi WA, Oliveira AA, França TC, Krettli AU (2011) Antimalarial activity of potential inhibitors of Plasmodium falciparum lactate dehydrogenase enzyme selected by docking studies. PLoS One 6: e21237.J. Penna-CoutinhoWA CortopassiAA OliveiraTC FrançaAU Krettli2011Antimalarial activity of potential inhibitors of Plasmodium falciparum lactate dehydrogenase enzyme selected by docking studies.PLoS One6e21237

26. Dios AC, Casabianca , LB , Kosar A, Roepe PD (2004) Structure of the Amodiaquine-FFIX Oxo dimer solution complex at atomic resolution. Inorg Chem 43: 8078–8084.AC DiosCasabiancaLBA. KosarPD Roepe2004Structure of the Amodiaquine-FFIX Oxo dimer solution complex at atomic resolution.Inorg Chem4380788084

27. Vippagunta SR, Dorn A, Matile H, Bhattacharjee AK, Karle JM, et al. (1999) Structural specificity of chloroquine-hematin binding related to inhibition of hematin polymerization and parasite growth. J Med Chem 42: 4630–4639.SR VippaguntaA. DornH. MatileAK BhattacharjeeJM Karle1999Structural specificity of chloroquine-hematin binding related to inhibition of hematin polymerization and parasite growth.J Med Chem4246304639

28. Leed A, Dubay K, Ursos LMB, Sears D, Dios AC, Roepe PD (2002) Solution structures of antimalarial drug-heme complexes. Biochemistry 41: 10245–10255.A. LeedK. DubayLMB UrsosD. SearsAC DiosPD Roepe2002Solution structures of antimalarial drug-heme complexes.Biochemistry411024510255

29. Cortopassi WA, Oliveira AA, Guimarães AP, Rennó MN, Krettli AU, et al. (2011) Docking studies on the binding of quinoline derivatives and hematin to Plasmodium falciparum lactate dehydrogenase. J Biomol Struct Dyn 29: 207–218.WA CortopassiAA OliveiraAP GuimarãesMN RennóAU Krettli2011Docking studies on the binding of quinoline derivatives and hematin to Plasmodium falciparum lactate dehydrogenase.J Biomol Struct Dyn29207218

30. Read J, Wilkinson K, Tranter R, Sessions R, Brady R (1999) Chloroquine binds in the cofactor binding site of Plasmodium falciparum lactate dehydrogenase. J Biol Chem 274: 10213–10218.J. ReadK. WilkinsonR. TranterR. SessionsR. Brady1999Chloroquine binds in the cofactor binding site of Plasmodium falciparum lactate dehydrogenase.J Biol Chem2741021310218

31. Chellan P, Nasser S, Vivas L, Chibale K, Smith GS (2010) Cyclopalladated complexes containing tridentate thiosemicarbazone ligands of biological significance: Synthesis, structure and antimalarial activity. J.Organomet. Chem. 695: 2225–2232.P. ChellanS. NasserL. VivasK. ChibaleGS Smith2010Cyclopalladated complexes containing tridentate thiosemicarbazone ligands of biological significance: Synthesis, structure and antimalarial activity. J.Organomet. Chem.69522252232

32. Sánchez-Delgado RA, Navarro M, Pérez H, Urbina JA (1996) Toward a novel metal-based chemotherapy against tropical diseases. 2. Synthesis and antimalarial activity in vitro and in vivo of new ruthenium- and rhodium-chloroquine complexes. J Med Chem 39: 1095–1099.RA Sánchez-DelgadoM. NavarroH. PérezJA Urbina1996Toward a novel metal-based chemotherapy against tropical diseases. 2. Synthesis and antimalarial activity in vitro and in vivo of new ruthenium- and rhodium-chloroquine complexes.J Med Chem3910951099

33. Navarro M, Pérez H, Sánchez-Delgado RA (1997) Toward a novel metal-based chemotherapy against tropical diseases. 3. Synthesis and antimalarial activity in vitro and in vivo of the new gold-chloroquine complex [Au(PPh3)(CQ)]PF6. J Med Chem 40: 1937–1939.M. NavarroH. PérezRA Sánchez-Delgado1997Toward a novel metal-based chemotherapy against tropical diseases. 3. Synthesis and antimalarial activity in vitro and in vivo of the new gold-chloroquine complex [Au(PPh3)(CQ)]PF6.J Med Chem4019371939

34. Gasser G, Ott I, Metzler-Nolte N (2011) Organometallic anticancer compounds. J Med Chem 54: 3–25.G. GasserI. OttN. Metzler-Nolte2011Organometallic anticancer compounds.J Med Chem54325

35. Galanski M, Jakupec MA, Keppler BK (2005) Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches. Curr Med Chem 12: 2075–2094.M. GalanskiMA JakupecBK Keppler2005Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches.Curr Med Chem1220752094

36. Gabbiani C, Messori L, Cinellu MA, Casini A, Mura P, et al. (2009) Outstanding plasmodicidal properties within a small panel of metallic compounds: Hints for the development of new metal-based antimalarials. J Inorg Biochem 103: 310–312.C. GabbianiL. MessoriMA CinelluA. CasiniP. Mura2009Outstanding plasmodicidal properties within a small panel of metallic compounds: Hints for the development of new metal-based antimalarials.J Inorg Biochem103310312

37. Navarro M, Vásquez F, Sánchez-Delgado RA, Pérez H, Sinou V, et al. (2004) Toward a novel metal-based chemotherapy against tropical diseases. 7. Synthesis and in vitro antimalarial activity of new gold-chloroquine complexes. J Med Chem 47: 5204–5209.M. NavarroF. VásquezRA Sánchez-DelgadoH. PérezV. Sinou2004Toward a novel metal-based chemotherapy against tropical diseases. 7. Synthesis and in vitro antimalarial activity of new gold-chloroquine complexes.J Med Chem4752045209

38. Ajibade P A, Kolawole GA, O'Brien P, Helliwell M (2006) Synthesis and characterization of Ni(II), Pd(II) and Pt(II) complexes of 2,4-diamino-5-(3, 4, 5-trimethoxybenzyl) pyrimidine complexes. J Coord Chem 59: 1621–1628.A. Ajibade PGA KolawoleP. O'BrienM. Helliwell2006Synthesis and characterization of Ni(II), Pd(II) and Pt(II) complexes of 2,4-diamino-5-(3, 4, 5-trimethoxybenzyl) pyrimidine complexes.J Coord Chem5916211628

39. Musonda CC, Gut J, Rosenthal PJ, Yardley V, Carvalho de Souza RC, et al. (2006) Application of multicomponent reactions to antimalarial drug discovery. Part 2: New antiplasmodial and antitrypanosomal 4-aminoquinoline gamma- and delta-lactams via a ‘catch and release’ protocol. Bioorg Med Chem 14: 5605–5615.CC MusondaJ. GutPJ RosenthalV. YardleyRC Carvalho de Souza2006Application of multicomponent reactions to antimalarial drug discovery. Part 2: New antiplasmodial and antitrypanosomal 4-aminoquinoline gamma- and delta-lactams via a ‘catch and release’ protocol.Bioorg Med Chem1456055615

40. Zhang H, Solomon VR, Hu C, Ulibarri G, Lee H (2008) Synthesis and in vitro cytotoxicity evaluation of 4-aminoquinoline derivatives. Biomedicine & Pharmacotherapy 62: 65–69.H. ZhangVR SolomonC. HuG. UlibarriH. Lee2008Synthesis and in vitro cytotoxicity evaluation of 4-aminoquinoline derivatives.Biomedicine & Pharmacotherapy626569

41. Trager W, Jensen J (1976) Human malaria parasites in continuous culture. Science 193: 673–675.W. TragerJ. Jensen1976Human malaria parasites in continuous culture.Science193673675

42. de Andrade-Neto V, Goulart M, da Silva Filho J, da Silva M, Pinto MC, et al. (2004) Antimalarial activity of phenazines from lapachol, beta-lapachone and its derivatives against Plasmodium falciparum in vitro and Plasmodium berghei in vivo. Bioorg Med Chem Lett 14: 1145–1149.V. de Andrade-NetoM. GoulartJ. da Silva FilhoM. da SilvaMC Pinto2004Antimalarial activity of phenazines from lapachol, beta-lapachone and its derivatives against Plasmodium falciparum in vitro and Plasmodium berghei in vivo.Bioorg Med Chem Lett1411451149

43. Lambros C, Vanderberg J (1979) Synchronization of Plasmodium falciparum erythrocytic stages in culture. J Parasitol 65: 418–420.C. LambrosJ. Vanderberg1979Synchronization of Plasmodium falciparum erythrocytic stages in culture.J Parasitol65418420

44. Xu L, Chaudhuri A (2005) Plasmodium yoelii: a differential fluorescent technique using Acridine Orange to identify infected erythrocytes and reticulocytes in Duffy knockout mouse. Exp Parasitol 110: 80–87.L. XuA. Chaudhuri2005Plasmodium yoelii: a differential fluorescent technique using Acridine Orange to identify infected erythrocytes and reticulocytes in Duffy knockout mouse.Exp Parasitol1108087

45. Desjardins R, Canfield C, Haynes J, Chulay J (1979) Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob Agents Chemother 16: 710–718.R. DesjardinsC. CanfieldJ. HaynesJ. Chulay1979Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique.Antimicrob Agents Chemother16710718

46. Andrade-Neto V, Brandão M, Oliveira F, Casali V, Njaine B, et al. (2004) Antimalarial activity of Bidens pilosa L. (Asteraceae) ethanol extracts from wild plants collected in various localities or plants cultivated in humus soil. Phytother Res 18: 634–639.V. Andrade-NetoM. BrandãoF. OliveiraV. CasaliB. Njaine2004Antimalarial activity of Bidens pilosa L. (Asteraceae) ethanol extracts from wild plants collected in various localities or plants cultivated in humus soil.Phytother Res18634639

47. Ncokazi KK, Egan TJ (2005) A colorimetric high-throughput beta-hematin inhibition screening assay for use in the search for antimalarial compounds. Anal Biochem 338: 306–319.KK NcokaziTJ Egan2005A colorimetric high-throughput beta-hematin inhibition screening assay for use in the search for antimalarial compounds.Anal Biochem338306319

48. Peters W (1965) Drug resistance in Plasmodium berghei Vincke and Lips, 1948. I. Chloroquine resistance. Exp Parasitol 17: 80–89.W. Peters1965Drug resistance in Plasmodium berghei Vincke and Lips, 1948. I. Chloroquine resistance.Exp Parasitol178089

49. Carvalho L, Brandão M, Santos-Filho D, Lopes J, Krettli A (1991) Antimalarial activity of crude extracts from Brazilian plants studied in vivo in Plasmodium berghei-infected mice and in vitro against Plasmodium falciparum in culture. Braz J Med Biol Res 24: 1113–1123.L. CarvalhoM. BrandãoD. Santos-FilhoJ. LopesA. Krettli1991Antimalarial activity of crude extracts from Brazilian plants studied in vivo in Plasmodium berghei-infected mice and in vitro against Plasmodium falciparum in culture.Braz J Med Biol Res2411131123

50. Denizot F, Lang R (1986) Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 89: 271–277.F. DenizotR. Lang1986Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability.J Immunol Methods89271277

51. Borenfreunda E, Babicha H, Martin-Alguacila N (1987) Comparisons of two in vitro cytotoxicity assays: The neutral red (NR) and tetrazolium MTT tests. Toxicology in vitro 2: 1–6.E. BorenfreundaH. BabichaN. Martin-Alguacila1987Comparisons of two in vitro cytotoxicity assays: The neutral red (NR) and tetrazolium MTT tests.Toxicology in vitro216

52. Madureira MC, Martins AP, Gomes M, Paiva J, Proença da Cunha A, et al. (2002) Antimalarial activity of medicinal plants used in traditional medicine in S Tomé and Príncipe islands. J. Ethnopharmacol 8: 23–29.MC MadureiraAP MartinsM. GomesJ. PaivaA. Proença da Cunha2002Antimalarial activity of medicinal plants used in traditional medicine in S Tomé and Príncipe islands.J. Ethnopharmacol82329

53. Wang C, Qin X, Huang B, He F, Zeng C (2010) Hemolysis of human erythrocytes induced by melamine-cyanurate complex. Biochem Biophys Res Commun 402: 773–777.C. WangX. QinB. HuangF. HeC. Zeng2010Hemolysis of human erythrocytes induced by melamine-cyanurate complex.Biochem Biophys Res Commun402773777

54. Frisch MJ (2003) Gaussian 03, Revision C.02 Gaussian, Inc. MJ Frisch2003Gaussian 03, Revision C.02 Gaussian, Inc

55. Thomsen R, Christensen M (2006) MolDock: a new technique for high-accuracy molecular docking. J Med Chem 49: 3315–3321.R. ThomsenM. Christensen2006MolDock: a new technique for high-accuracy molecular docking.J Med Chem4933153321

56. Bernstein F, Koetzle T, Williams G, Meyer EJ, Brice M, et al. (1977) The Protein Data Bank: a computer-based archival file for macromolecular structures. J Mol Biol 112: 535–542.F. BernsteinT. KoetzleG. WilliamsEJ MeyerM. Brice1977The Protein Data Bank: a computer-based archival file for macromolecular structures.J Mol Biol112535542

57. Berman H, Battistuz T, Bhat T, Bluhm W, Bourne P, et al. (2002) The Protein Data Bank. Acta Crystallogr D Biol Crystallogr 58: 899–907.H. BermanT. BattistuzT. BhatW. BluhmP. Bourne2002The Protein Data Bank.Acta Crystallogr D Biol Crystallogr58899907